HRP20190628T1 - Sredstva za liječenje tumora, njihova uporaba i postupak iste - Google Patents
Sredstva za liječenje tumora, njihova uporaba i postupak iste Download PDFInfo
- Publication number
- HRP20190628T1 HRP20190628T1 HRP20190628TT HRP20190628T HRP20190628T1 HR P20190628 T1 HRP20190628 T1 HR P20190628T1 HR P20190628T T HRP20190628T T HR P20190628TT HR P20190628 T HRP20190628 T HR P20190628T HR P20190628 T1 HRP20190628 T1 HR P20190628T1
- Authority
- HR
- Croatia
- Prior art keywords
- blocking antibody
- use according
- cancer
- radiation treatment
- antibody
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 4
- 238000000034 method Methods 0.000 title claims 3
- 230000000903 blocking effect Effects 0.000 claims 14
- 230000005855 radiation Effects 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oncology (AREA)
- Compounds Of Unknown Constitution (AREA)
Claims (11)
1. Antitijelo koje blokira B7-H1 za uporabu u postupku liječenja raka u kombinaciji s liječenjem radijacijom, pri čemu je antitijelo koje blokira B7-H1 primijenjeno nakon liječenja radijacijom, i pri čemu navedeno antitijelo koje blokira B7-H1 je anti-B7-H1 antitijelo.
2. Antitijelo koje blokira B7-H1 za uporabu prema zahtjevu 1, koje je monoklonsko antitijelo za B7-H1.
3. Antitijelo koje blokira B7-H1 za uporabu prema bilo kojem od zahtjeva 1-2, pri čemu liječenje radijacijom je iradijacija X-zrakama.
4. Antitijelo koje blokira B7-H1 za uporabu prema zahtjevu 3, pri čemu liječenje radijacijom je jednostruka ili višestruka iradijacija X-zrakama.
5. Antitijelo koje blokira B7-H1 za uporabu prema bilo kojem od zahtjeva 3-4, pri čemu liječenje radijacijom je 1, 2, 3, 4, 5, 6 ili više iradijacija X-zrakama.
6. Antitijelo koje blokira B7-H1 za uporabu prema bilo kojem od zahtjeva 3-5, pri čemu doza X-zraka korištena u svakoj iradijaciji je 5-20 Gy.
7. Antitijelo koje blokira B7-H1 za uporabu prema zahtjevu 6, pri čemu doza X-zraka korištena u svakoj iradijaciji je 5-8, 5-12 ili 5-15 Gy.
8. Antitijelo koje blokira B7-H1 za uporabu prema bilo kojem od zahtjeva 1-7, pri čemu je rak odabran od skupine koja se sastoji od raka dojke, raka jajnika, raka mjehura, raka pluća, raka prostate, raka gušterače, raka debelog crijeva i melanoma.
9. Antitijelo koje blokira B7-H1 za uporabu prema zahtjevu 8, pri čemu rak je rak dojke ili rak prostate.
10. Antitijelo koje blokira B7-H1 za uporabu prema bilo kojem od zahtjeva 1-9, pri čemu navedeni postupak dalje sadrži primjenu kemoterapijskog sredstva.
11. Antitijelo koje blokira B7-H1 za uporabu prema bilo kojem od zahtjeva 1-10, pri čemu se navedeno antitijelo koje blokira B7-H1 primjenjuje unutar 9 dana nakon liječenja radijacijom.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13870762.5A EP2944323B1 (en) | 2013-01-11 | 2013-01-11 | Agents for treating tumours, use and method thereof |
| PCT/CN2013/070342 WO2014107873A1 (zh) | 2013-01-11 | 2013-01-11 | 用于肿瘤治疗的试剂、其用途及方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190628T1 true HRP20190628T1 (hr) | 2019-06-14 |
Family
ID=51166501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190628TT HRP20190628T1 (hr) | 2013-01-11 | 2019-04-01 | Sredstva za liječenje tumora, njihova uporaba i postupak iste |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20150344577A1 (hr) |
| EP (1) | EP2944323B1 (hr) |
| CA (1) | CA2896797A1 (hr) |
| DK (1) | DK2944323T3 (hr) |
| ES (1) | ES2721168T3 (hr) |
| HR (1) | HRP20190628T1 (hr) |
| WO (1) | WO2014107873A1 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
| WO2013009701A2 (en) | 2011-07-08 | 2013-01-17 | The University Of North Carolina At Chapel Hill | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
| ES2746805T3 (es) | 2013-12-12 | 2020-03-06 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo |
| EP3083686B2 (en) | 2013-12-17 | 2023-03-22 | F. Hoffmann-La Roche AG | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| US10806694B2 (en) | 2014-10-14 | 2020-10-20 | The University Of Chicago | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof |
| JP6731404B2 (ja) * | 2014-10-14 | 2020-07-29 | ザ ユニバーシティ オブ シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 光線力学療法、ｘ線誘起光線力学療法、放射線療法、化学療法、免疫療法、及びこれらの任意の組み合わせのためのナノ粒子 |
| EP3268392A2 (en) | 2015-03-13 | 2018-01-17 | CytomX Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| JP6896650B2 (ja) | 2015-06-17 | 2021-06-30 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法 |
| SG10201913303XA (en) | 2015-07-13 | 2020-03-30 | Cytomx Therapeutics Inc | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| US10323091B2 (en) | 2015-09-01 | 2019-06-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| WO2017201528A1 (en) | 2016-05-20 | 2017-11-23 | The University Of Chicago | Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof |
| MA50948A (fr) | 2016-12-07 | 2020-10-14 | Agenus Inc | Anticorps et procédés d'utilisation de ceux-ci |
| AU2018278327B2 (en) | 2017-06-01 | 2023-03-16 | Cytomx Therapeutics, Inc. | Activatable anti-pdl1 antibodies and methods of use thereof |
| WO2019028250A1 (en) | 2017-08-02 | 2019-02-07 | The University Of Chicago | NOMOGENEOUS ORGANOMETALLIC ORGANOMETRIC ORGANOMETRIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RODIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100285039A1 (en) * | 2008-01-03 | 2010-11-11 | The Johns Hopkins University | B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells |
| CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
| CA2992770A1 (en) * | 2009-11-24 | 2011-06-03 | Medimmune Limited | Targeted binding agents against b7-h1 |
| CN103796680A (zh) * | 2011-06-21 | 2014-05-14 | 约翰霍普金斯大学 | 用于增强针对赘生物的基于免疫的治疗的聚焦放射 |
| US20150024008A1 (en) * | 2011-11-21 | 2015-01-22 | The University Of Chicago | Methods and Compositions Involving Induced Senescent Cells for Cancer Treatment |
| EA036814B9 (ru) | 2011-11-28 | 2021-12-27 | Мерк Патент Гмбх | Антитело против pd-l1 (варианты), композиция, содержащая это антитело, и их применение |
-
2013
- 2013-01-11 DK DK13870762.5T patent/DK2944323T3/en active
- 2013-01-11 CA CA2896797A patent/CA2896797A1/en not_active Abandoned
- 2013-01-11 EP EP13870762.5A patent/EP2944323B1/en not_active Revoked
- 2013-01-11 ES ES13870762T patent/ES2721168T3/es active Active
- 2013-01-11 WO PCT/CN2013/070342 patent/WO2014107873A1/zh active Application Filing
- 2013-01-11 US US14/654,648 patent/US20150344577A1/en not_active Abandoned
-
2019
- 2019-04-01 HR HRP20190628TT patent/HRP20190628T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014107873A1 (zh) | 2014-07-17 |
| DK2944323T3 (en) | 2019-04-15 |
| EP2944323A4 (en) | 2016-07-27 |
| US20150344577A1 (en) | 2015-12-03 |
| ES2721168T3 (es) | 2019-07-29 |
| CA2896797A1 (en) | 2014-07-17 |
| EP2944323B1 (en) | 2019-03-27 |
| EP2944323A1 (en) | 2015-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190628T1 (hr) | Sredstva za liječenje tumora, njihova uporaba i postupak iste | |
| MX2021004828A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
| BR112019021822A2 (pt) | Terapia de combinação | |
| CL2015003285A1 (es) | Arilquinazolinas | |
| MX2023003470A (es) | Anticuerpo anti-garp. | |
| BR112017000703A2 (pt) | métodos para tratar ou retardar a progressão do câncer, para reduzir ou inibir a reincidência do câncer, para tratar ou retardar a progressão da imunidade tumoral e para aumentar, intensificar ou estimular uma resposta ou função imune e kit | |
| MX2019008701A (es) | Terapia de combinacion que involucra compuestos macrociclicos de diarilo. | |
| BR112015016796A2 (pt) | modulador de receptor de androgênio e usos do mesmo | |
| MX2018011054A (es) | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| TW200730532A (en) | Camptothecin derivatives as chemoradiosensitizing agents | |
| BR112015030377A2 (pt) | preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação | |
| HRP20211177T1 (hr) | Korteksolon 17alfa-valerat za uporabu u liječenju tumora | |
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| PH12018500701A1 (en) | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer | |
| BR112017023517A2 (pt) | anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20 | |
| MY189663A (en) | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer | |
| BR112015027474A8 (pt) | anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo. | |
| PH12015502260A1 (en) | C. novyi for the treatment of solid tumors in humans | |
| SG11202009649RA (en) | Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer | |
| BR112018011045A2 (pt) | inibidores de oligonucleotídeo anti-sentido (aso) de transportador de monocarboxilato 4 (mct4) para uso como terapêutica no tratamento de câncer | |
| MX2017010341A (es) | Terapia para cancer con un parvovirus combinado con bevacizumab. | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
| BR112019025164A2 (pt) | Esquema de dosagem para tesetaxel e capecitabina |